San Diego, CA, July 18, 2025  Acadia Pharmaceuticals, a leader in treatments for neurological and rare diseases, has unveiled an ambitious roadmap at its first-ever R&D Day, projecting annual revenues of up to $14 billion. The company credits this bold forecast to its robust portfolio of marketed therapies and a promising pipeline of seven experimental assets in preclinical and clinical stages.

Currently, Acadia markets Daybue for Rett syndrome and Nuplazid approved by the FDA in 2016 as the first treatment for delusions and hallucinations associated with Parkinson’s disease psychosis. Advancing its neuroscience focus, the company is progressing ACP-204 through Phase 2 trials targeting Lewy body dementia and Alzheimer’s disease psychosis.

A key milestone in Acadia’s evolution is the appointment of Elizabeth (Liz) Thompson as the new Head of Research and Development, succeeding Owen Adams. Together, Thompson and Adams are reshaping Acadia’s strategy to elevate it from a mid-sized biotech to what Adams describes as a “biotech powerhouse.”

“Memory loss alone isn’t what leads families to consider long-term care it’s often the severe psychosis and agitation,” Adams noted. “Our goal is to bring transformative therapies that can ease this burden.”

With competitors like AbbVie and Bristol Myers Squibb in the Alzheimer’s space, Acadia’s differentiated focus on symptomatic treatments positions it as a pivotal player in the neurodegenerative disease market.

Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com